Precigen, Inc. Common Stock (PGEN) is a publicly traded Healthcare sector company. As of May 21, 2026, PGEN trades at $4.27 with a market cap of $1.45B and a P/E ratio of -3.12. PGEN moved +2.40% today. Year to date, PGEN is +2.15%; over the trailing twelve months it is +202.84%. Its 52-week range spans $0.65 to $5.47. Analyst consensus is buy with an average price target of $11.00. Rallies surfaces PGEN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Precigen Reports $21.6M Q1 PAPZIMEOS Revenue and $0.02 EPS Loss: Precigen generated $21.6 million of Q1 net product revenue from PAPZIMEOS, enrolled 400 patients (25% in community settings), and reported a $0.02 per-share loss versus a $0.03 consensus loss. Cash and equivalents totaled $56.7 million as of March 31, 2026, and management forecasts cash-flow break-even by year-end.
| Metric | Value |
|---|---|
| Price | $4.27 |
| Market Cap | $1.45B |
| P/E Ratio | -3.12 |
| EPS | $-1.37 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.47 |
| 52-Week Low | $0.65 |
| Volume | 19 |
| Avg Volume | 0 |
| Revenue (TTM) | $9.68M |
| Net Income | $-250.64M |
| Gross Margin | 0.00% |
2 analysts cover PGEN: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $11.00.